Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LG Life Science Tops R&D Investment List of Korea-Listed Pharmas

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Of the 37 local Korean pharmas listed on Korea's main KOSPI stock market, LG Life Science topped local pharmas in R&D investment last year in both scale and in proportion to its sales, according to a report released by a lawmaker in an Oct. 6 National Assembly session

You may also be interested in...



Korea Biosimilar Play LG Life Sciences Names New CEO Amid Unfriendly Business Conditions

SEOUL - LG Life Sciences has reshuffled its top management and named Jung Il-Jae as new CEO and President. Kim In-Chull had served as president of LG Life Sciences since 2006, and took the lead in aggressively moving the company into the biosimilar space. The company said only that Kim will now serve as an advisor to the company

Korea Biosimilar Play LG Life Sciences Names New CEO Amid Unfriendly Business Conditions

SEOUL - LG Life Sciences has reshuffled its top management and named Jung Il-Jae as new CEO and President. Kim In-Chull had served as president of LG Life Sciences since 2006, and took the lead in aggressively moving the company into the biosimilar space. The company said only that Kim will now serve as an advisor to the company

LG Life Sciences' 2nd Quarter Sales Dampened By Strong Won, Tightened Regulatory Watch On Pharma

SEOUL - The ongoing appreciation of the Korean won vs. the U.S. dollar and a tighter government grip on pharmas to detect malpractices such as rebates - or kickbacks - in the local pharma industry adversely affected the second quarter earnings of LG Life Sciences

Related Content

UsernamePublicRestriction

Register

SC070248

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel